Related Experiment Videos
Human immunodeficiency virus and respiratory infection
E A Ashley1, M A Johnson, M C Lipman
1Department of Thoracic and HIV Medicine, The Royal Free Hospital, London, United Kingdom.
Current Opinion in Pulmonary Medicine
|April 27, 2000
Summary
Pulmonary disease is a significant concern for individuals with human immunodeficiency virus (HIV). Advances in antiretroviral therapy have reduced associated deaths, but challenges like drug-resistant infections and tuberculosis persist.
Area of Science:
- Infectious Diseases
- Pulmonology
- Public Health
Background:
- Pulmonary disease significantly impacts the 33 million individuals infected with human immunodeficiency virus (HIV) globally.
- Respiratory infections contribute to a substantial portion of annual HIV-related deaths.
- Highly active antiretroviral therapy (HAART) has reduced HIV-associated morbidity and mortality by up to 80% in accessible regions.
Purpose of the Study:
- To review the current landscape of pulmonary disease in HIV-infected individuals.
- To discuss the impact of HAART on opportunistic infection prophylaxis.
- To highlight ongoing challenges including drug-resistant Pneumocystis carinii and tuberculosis.
Main Methods:
- Literature review of recent studies and recommendations.
- Analysis of the impact of HAART on clinical outcomes.
- Discussion of treatment complexities and prophylaxis strategies.
Main Results:
- HAART has enabled the discontinuation of specific opportunistic infection prophylaxis in immune-restored patients.
- Reports of drug-resistant Pneumocystis carinii isolates are increasing, though clinical relevance is debated.
- The interaction between anti-HIV and anti-tuberculosis treatments remains complex.
- The importance of immunization and prophylaxis against bacterial and mycobacterial infections in developing countries has been further defined.
Conclusions:
- While HAART has improved outcomes, pulmonary disease remains a critical issue in HIV management.
- Ongoing research is needed to address drug resistance and optimize treatment strategies for co-infections like tuberculosis.
- Prophylaxis and immunization remain vital, particularly in resource-limited settings.